EU Tightens Guidelines on Antibiotic Use to Combat Resistance

The European Union has introduced stricter regulations regarding the use of antibiotics, particularly azithromycin, in an effort to address the growing issue of antimicrobial resistance. This move comes as health authorities raise concerns over the increasing number of resistant infections, which are estimated to claim tens of thousands of lives annually across Europe.

Antibiotic resistance has emerged as a significant challenge for medical professionals, largely driven by the excessive and inappropriate prescription of these drugs. According to the European Centre for Disease Prevention and Control (ECDC), resistant bacterial infections are responsible for approximately 35,000 deaths each year in the region. The problem is further compounded by the limited availability of new antibiotics, resulting in ongoing reliance on established medications that have been available for decades.

To address this, the German Federal Institute for Drugs and Medical Devices (BfArM) initiated a harmonization process at the European level focused on azithromycin. The goal was to standardize indications and dosing recommendations across EU member states, reducing unnecessary prescriptions and fostering more targeted use. This assessment concluded with updated guidelines and safety warnings applicable throughout the European Union.

Azithromycin has a long history of use in treating various infections in both adults and children. It is also listed by the World Health Organization (WHO) as an essential medicine, yet carries a high risk for promoting resistance if misused. Recent data indicate a rise in azithromycin prescriptions, prompting the need for a thorough review of its approved uses.

The revised guidelines now specify that azithromycin should no longer be prescribed for conditions such as acne, Helicobacter pylori infections, or for the prevention of asthma exacerbations, as clinical benefit in these indications was not sufficiently demonstrated. These restrictions apply to both oral and intravenous forms of the medication. In addition, the remaining approved uses have been more clearly defined to identify appropriate patient groups and ensure that treatment is reserved for cases where it is most effective.

All products containing azithromycin will now include safety warnings highlighting the potential for resistance development. Healthcare professionals are advised to consider azithromycin only after careful assessment, particularly when alternative antibiotics such as beta-lactams cannot be used due to allergies or existing resistance patterns. The updated product information is also expected to be reflected in clinical guidelines and antibiotic stewardship programs, further promoting responsible prescribing practices among medical professionals.

Experts emphasize that these changes are crucial to preserving the effectiveness of existing antibiotics for as long as possible. With new antibiotic development lagging behind the growing threat of resistant bacteria, coordinated actions at the European level are seen as essential for safeguarding public health and ensuring effective treatment options remain available in the future.